Gujarat Themis Biosyn Limited

GUJTHEM6

INE942C01045

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:54 14/06/2024 pm IST			5-day change	1st Jan Change
464.4 ^INR	-1.20%		+14.01%	+81.02%

14/05	Gujarat Themis Biosyn Gets Board Nod for Issue of Bonus Shares	MT
14/05	Gujarat Themis Biosyn Names Technology Chief	MT

Gujarat Themis Biosyn Limited Appoints Han Kon Kim as an Additional (Non Executive) Director with Effect from January 13 2021

January 14, 2021 at 06:37 pm IST

Gujarat Themis Biosyn Limited have appointed Mr. Han Kon Kim as an Additional (Non Executive) Director with effect from January 13 2021 on the Board of the Company to hold office till the conclusion of the next Annual General Meeting of the Company.

Latest news about Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Gets Board Nod for Issue of Bonus Shares	14/05	MT
Gujarat Themis Biosyn Names Technology Chief	14/05	MT
Gujarat Themis Biosyn Limited Recommends Dividend for Financial Year Ended March 31, 2024, Payable on or After July 15, 2024	14/05	CI
Gujarat Themis Biosyn Limited Approves Management Changes	14/05	CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	14/05	CI
Gujarat Themis Biosyn Limited Approves an Interim Dividend for the Year 2023-24	10/02	CI
Gujarat Themis Biosyn Limited Approves Interim Dividend for the Financial Year 2023-24	10/02	CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	10/02	CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	04/11	CI
Gujarat Themis Biosyn Limited Recommends Dividend for Financial Year Ended March 31, 2023	13/23/13	CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	13/23/13	CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	03/23/03	CI
Gujarat Themis Biosyn Names New CEO	05/23/05	MT
Gujarat Themis Biosyn Limited Appoints Tapas Guha Thakurata as Chief Executive Officer	05/23/05	CI
Gujarat Themis Biosyn Board Declares Interim Dividend for Fiscal 2023	21/22/21	MT
Gujarat Themis Biosyn Limited Approves Declaration of an Interim Dividend for the Financial Year 2022-23	21/22/21	CI
Gulf Oil Lubricants' Net Profit Slides in Fiscal Q2	09/22/09	MT
Gujarat Themis Biosyn's Net Profit Climbs in Fiscal Q2	09/22/09	MT
Gujarat Themis Biosyn Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	07/22/07	CI
Themis Medicare Limited entered into share purchase agreement to acquire additional 6.47% stake in Gujarat Themis Biosyn Limited from Pharmaceutical Business Group Limited for approximately INR 700 million.	07/22/07	CI
Gujarat Themis Biosyn Limited Recommends Dividend for the Financial Year 2021-22	13/22/13	CI
CARE Upgrades Rating on Gujarat Themis Biosyn's Long-term Bank Financing; Outlook Stable	05/22/05	MT
Gujarat Themis Biosyn Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	27/22/27	CI
Gujarat Themis Biosyn CEO Steps Down	11/22/11	MT
Gujarat Themis Biosyn Limited Announces Resignation of Mr. Jagadish O. Kauiaigi, Chief Executive Officer	11/22/11	CI

Chart Gujarat Themis Biosyn Limited

Duration

Period

More charts

Company Profile

Gujarat Themis Biosyn Limited is an India-based company, which is principally engaged in the manufacturing of pharmaceuticals and medicinal chemical products. The Company is focused on the business of manufacturing and sale of finished active pharmaceutical ingredients (API) products by fermentation process. The Company operates through manufacturing of the bulk drugs segment. Its product portfolio comprises Rifamycin-O and Rifamycin-S. The Company is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin (an Antibiotic used for the treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease.) and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin (this is an Antibiotic used for treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy). Its research and development division focuses on developing fermentation cultures.

Sector

Pharmaceuticals

Calendar

16/07/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
GUJARAT THEMIS BIOSYN LIMITED	+81.02%	404M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.37%	43.54B
OTSUKA HOLDINGS CO., LTD.	+18.30%	21.78B
SANDOZ GROUP AG	+18.74%	15.38B
CIPLA LIMITED	+25.55%	15.12B
ZYDUS LIFESCIENCES LIMITED	+60.99%	13.36B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-14.84%	6.38B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.17%	5.32B